HUP0002053A2 - Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity - Google Patents
Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesityInfo
- Publication number
- HUP0002053A2 HUP0002053A2 HU0002053A HUP0002053A HUP0002053A2 HU P0002053 A2 HUP0002053 A2 HU P0002053A2 HU 0002053 A HU0002053 A HU 0002053A HU P0002053 A HUP0002053 A HU P0002053A HU P0002053 A2 HUP0002053 A2 HU P0002053A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- obesity
- diabetes
- treatment
- reduce
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 3
- 235000020824 obesity Nutrition 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- MYEFHJZLNOFLNK-UHFFFAOYSA-N benzenesulfonamide;1,3-thiazole Chemical class C1=CSC=N1.NS(=O)(=O)C1=CC=CC=C1 MYEFHJZLNOFLNK-UHFFFAOYSA-N 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 1
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 1
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004130 lipolysis Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
A találmány tárgya új, (I) általános képletű, tiazol-benzol--szulfonamidok mint <3 agonisták elhízás és diabétesz kezelésére és azezeket tartalmazó gyógyszerkészítmények. A vegyületek <3 adrenergreceptor agonisták, amelyek igen kevés <1 és <2 adrenerg receptorhatást mutatnak, és ezért a vegyületek alkalmasak lipolízis növeléséreés energiafelhasználás növelésére a sejtekben. ═gy a vegyületekhatásosak II. típusú diabétesz és elhízás kezelésére. A vegyületeketalkalmazhatjuk a trigliceridszint csökkentésére, a koleszterinszintcsökkentésére vagy a nagy sűrűségű lipoprotein szint növelésére,bélmozgás csökkentésére. Ezen kívül a vegyületeket alkalmazhatjukneurogén gyulladás csökkentésére vagy antidepresszáns szerként. ÓThe subject of the invention is new, general formula (I), thiazole-benzenesulfonamides as <3 agonists for the treatment of obesity and diabetes and pharmaceutical preparations containing them. The compounds are <3 adrenergic receptor agonists, which show very little <1 and <2 adrenergic receptor effects, and therefore the compounds are suitable for increasing lipolysis and energy utilization in cells. ═and the compounds are effective II. for the treatment of type 2 diabetes and obesity. The compounds can be used to reduce triglyceride levels, reduce cholesterol levels, increase high-density lipoprotein levels, and reduce bowel movements. In addition, the compounds can be used to reduce neurogenic inflammation or as antidepressants. HE
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3676097P | 1997-01-28 | 1997-01-28 | |
GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
PCT/US1998/001317 WO1998032753A1 (en) | 1997-01-28 | 1998-01-23 | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0002053A2 true HUP0002053A2 (en) | 2001-08-28 |
HUP0002053A3 HUP0002053A3 (en) | 2001-09-28 |
Family
ID=26311166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0002053A HUP0002053A3 (en) | 1997-01-28 | 1998-01-23 | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0968209A1 (en) |
JP (1) | JP2001509166A (en) |
KR (1) | KR20000070568A (en) |
CN (1) | CN1251099A (en) |
AR (1) | AR011092A1 (en) |
AU (1) | AU728812B2 (en) |
BG (1) | BG103686A (en) |
BR (1) | BR9807096A (en) |
CA (1) | CA2278739A1 (en) |
EA (1) | EA199900692A1 (en) |
EE (1) | EE9900328A (en) |
HR (1) | HRP980044A2 (en) |
HU (1) | HUP0002053A3 (en) |
ID (1) | ID22273A (en) |
IL (1) | IL131130A0 (en) |
IS (1) | IS5131A (en) |
NO (1) | NO993646L (en) |
PE (1) | PE52299A1 (en) |
PL (1) | PL334833A1 (en) |
SK (1) | SK100099A3 (en) |
TR (1) | TR199902442T2 (en) |
WO (1) | WO1998032753A1 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19824175A1 (en) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino azole compounds |
CN1977842A (en) | 2000-01-21 | 2007-06-13 | 诺瓦提斯公司 | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
EP1258253A1 (en) * | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
ES2217090T3 (en) | 2000-03-31 | 2004-11-01 | Pfizer Products Inc. | PROCEDURE FOR PREPARATION OF REPLACED PYRIDINS. |
AU2001272917A1 (en) | 2000-07-13 | 2002-01-30 | Eli Lilly And Company | Beta3 adrenergic agonists |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
US6498170B2 (en) * | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
ATE329901T1 (en) | 2000-11-10 | 2006-07-15 | Lilly Co Eli | 3-SUBSTITUTED OXINDOL DERIVATIVES AS BETA-3 AGONISTS |
AU2002221080A1 (en) * | 2000-12-08 | 2002-06-18 | Masami Kusaka | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof |
AR035605A1 (en) | 2000-12-11 | 2004-06-16 | Bayer Corp | DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS |
AR035858A1 (en) | 2001-04-23 | 2004-07-21 | Bayer Corp | CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS |
CA2450562A1 (en) * | 2001-06-22 | 2003-01-03 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE60211199T2 (en) | 2001-08-14 | 2007-02-01 | Eli Lilly And Co., Indianapolis | 3-SUBSTITUTED OXINDOL BETA-3 AGONISTS |
ES2272749T3 (en) | 2001-08-14 | 2007-05-01 | Eli Lilly And Company | DERIVATIVES OF INDOL AS BETA-3 ADRENERGIC AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES. |
US20050014805A1 (en) * | 2001-10-12 | 2005-01-20 | Chenzhi Zhang | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
DE60204718T2 (en) | 2001-11-20 | 2006-05-18 | Eli Lilly And Co., Indianapolis | 3-SUBSTITUTED OXINDOL BETA 3 AGONISTS |
AU2002353844A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | Beta 3 adrenergic agonists |
US7009060B2 (en) | 2002-01-11 | 2006-03-07 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
WO2006132196A1 (en) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST |
CA2622608C (en) | 2005-09-14 | 2014-08-19 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
CA2624440A1 (en) * | 2005-10-04 | 2007-04-19 | Merck & Co., Inc. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
US8802695B2 (en) | 2010-02-03 | 2014-08-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN103476258B (en) | 2011-02-25 | 2017-04-26 | 默沙东公司 | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
EP2880028B1 (en) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
ES2394349B1 (en) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Use of selective beta-3 adrenergic receptor agonists for the treatment of pulmonary hypertension |
US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
CA2898482A1 (en) | 2013-02-22 | 2014-08-28 | Linda L. Brockunier | Antidiabetic bicyclic compounds |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
JP2016514671A (en) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists and uses thereof |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CA2913737A1 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0091749A3 (en) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/en not_active IP Right Cessation
- 1998-01-23 PL PL98334833A patent/PL334833A1/en unknown
- 1998-01-23 EE EEP199900328A patent/EE9900328A/en unknown
- 1998-01-23 ID IDW990755A patent/ID22273A/en unknown
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/en unknown
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/en not_active Application Discontinuation
- 1998-01-23 SK SK1000-99A patent/SK100099A3/en unknown
- 1998-01-23 CN CN98803585A patent/CN1251099A/en active Pending
- 1998-01-23 IL IL13113098A patent/IL131130A0/en unknown
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-23 JP JP53214898A patent/JP2001509166A/en active Pending
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/en not_active Application Discontinuation
- 1998-01-23 CA CA002278739A patent/CA2278739A1/en not_active Abandoned
- 1998-01-23 EP EP98903677A patent/EP0968209A1/en not_active Withdrawn
- 1998-01-23 EA EA199900692A patent/EA199900692A1/en unknown
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/en unknown
- 1998-01-27 AR ARP980100357A patent/AR011092A1/en unknown
- 1998-01-28 PE PE1998000064A patent/PE52299A1/en not_active Application Discontinuation
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/en not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/en unknown
- 1999-07-27 NO NO993646A patent/NO993646L/en not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL334833A1 (en) | 2000-03-27 |
EP0968209A1 (en) | 2000-01-05 |
EE9900328A (en) | 2000-02-15 |
CA2278739A1 (en) | 1998-07-30 |
JP2001509166A (en) | 2001-07-10 |
AU6038498A (en) | 1998-08-18 |
NO993646L (en) | 1999-09-27 |
AR011092A1 (en) | 2000-08-02 |
BG103686A (en) | 2000-06-30 |
SK100099A3 (en) | 2000-05-16 |
EA199900692A1 (en) | 2000-02-28 |
IS5131A (en) | 1999-07-23 |
CN1251099A (en) | 2000-04-19 |
ID22273A (en) | 1999-09-23 |
WO1998032753A1 (en) | 1998-07-30 |
AU728812B2 (en) | 2001-01-18 |
BR9807096A (en) | 2000-04-18 |
PE52299A1 (en) | 1999-05-26 |
IL131130A0 (en) | 2001-01-28 |
HRP980044A2 (en) | 1998-10-31 |
HUP0002053A3 (en) | 2001-09-28 |
NO993646D0 (en) | 1999-07-27 |
TR199902442T2 (en) | 2000-07-21 |
KR20000070568A (en) | 2000-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0002053A2 (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
FI972628A0 (en) | New sulfonamides | |
TR200000481T2 (en) | Derivatives of N-Alkoxyphenylalanine. | |
TW430664B (en) | Substituted carboxamidothiazoles, their preparation and pharmaceutical compositions containing them | |
HUP0104579A2 (en) | Glp-1 analogues, pharmaceutical compositions comprising thereof and their use | |
PT1075258E (en) | NEW FATAL ANALOGS FOR THE TREATMENT OF OBESITY | |
BR9506935A (en) | Compositions of sunscreen | |
KR940007025A (en) | 5- (2- (4- (1,2-benz isothiazol-3-yl) -1-piperazinyl) ethyl-6-chloro-1, 3-dihydro-2H-indol-2-one hydro Monochloride monohydrate | |
MXPA03000308A (en) | Beta3 adrenergic agonists. | |
MA26697A1 (en) | NOVEL GSK-3 INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
ATE319440T1 (en) | ANTIDIABETIC AGENTS | |
BR9713921A (en) | Compound, pharmaceutical composition, process for logician capable of being modulated through factor xa inhibition | |
ATE93863T1 (en) | ENZYME INHIBITING AMINO ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, COMPOSITIONS THEREOF AND THEIR USE. | |
ATE13765T1 (en) | 2-(1,4-BENZODIOXAN-2-YLALKYL)-IMIDAZOLE, THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THEM. | |
ATE80384T1 (en) | SULFURATED EICOSANOIDS AND THEIR USE IN PHARMACEUTICALS AND COSMETICS. | |
DE3870167D1 (en) | N- (VINBLASTINOYL-23) DERIVATIVES OF 1-AMINOMETHYLPOSPHONIC ACID, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME. | |
DE59006541D1 (en) | Means for protecting plants against diseases. | |
ATE158301T1 (en) | 4-AZA-PREGNAN-5-ALPHA-REDUCTASE ISOZYME 1 INHIBITORS | |
DK56687D0 (en) | 5-SUBSTITUTED OCTAHYDROINDOLIZIN COMPOUNDS AND 7-KETOMEL INTERMEDIATE PRODUCTS THEREOF | |
PT853478E (en) | Novel N-Acylated Derivatives of 4-HYDROXYPHENYLAMINE WITH ANALGESIC PROPERTIES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
TR199801683A2 (en) | New versions. | |
DE69029069D1 (en) | Use of xanthine derivatives against stomach ulcers | |
NO920031L (en) | SYNERGISTIC AGENT FOR THERAPEUTIC TREATMENT, PREPARATIONS CONTAINING THE ABOVE AGENT, AND USE OF THE AGENT FOR THE PREPARATION OF A MEDICINAL PREPARATION | |
PT75900A (en) | NEW OXYMES OF 3 '' '- DEHYDRO CARDENOLIDE TRIDIDITOXOSIDE METHODS FOR THEIR PREPARATION AND THEIR USE AS DRUGS | |
MX9605192A (en) | SUBSTITUTED SULFONAMIDES AS SELECTIVE 'beta'3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY. |